No abstract available
Plain language summary
This study examines the exposure of Medicare Part D beneficiaries to utilization management, such as prior authorization, for oral oncology drugs.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antineoplastic Agents* / economics
-
Antineoplastic Agents* / therapeutic use
-
Cost Sharing
-
Medicare Part D* / economics
-
Medicare Part D* / statistics & numerical data
-
Medicare Part D* / trends
-
Prescription Drugs / economics
-
Prescription Drugs / therapeutic use
-
United States / epidemiology
Substances
-
Prescription Drugs
-
Antineoplastic Agents